Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
Article in BMC Cancer (December 2022)
The most recent citing publication is shown below. View this citation on Dimensions.
Article in BMC Cancer (December 2022)